Quick Answer
Pacira BioSciences, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $726.41 million for the year ending 2025.
- Pacira BioSciences, Inc. showed an increase of +3.6% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Pacira BioSciences, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Pacira BioSciences, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 69.1%.
- Historical annual values: Fiscal year 2025: $726.41 million | Fiscal year 2024: $700.97 million | Fiscal year 2023: $674.98 million | Fiscal year 2022: $666.82 million | Fiscal year 2021: $541.53 million | Fiscal year 2020: $429.65 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: